Clinical Trial Update: Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the Drug [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and drug levels of inhalation powder CCI15106 in healthy adults and adults with moderate chronic obstructive pulmonary disease, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CCI15106 (CCI15106)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED | Results posted: 2019-09-27